You just read:

New Data Presented from Oncopeptides' Pivotal Phase 2 HORIZON Trial Evaluating Melflufen in Relapsed/Refractory Multiple Myeloma at 24th EHA Congress

News provided by

Oncopeptides AB

16 Jun, 2019, 15:09 BST